Fotagliptin
Fotagliptin (SAL067) is a DPP-4 inhibitor under development for the treatment of type 2 diabetes.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Fotagliptin (SAL067) is a DPP-4 inhibitor under development for the treatment of type 2 diabetes. Like other DPP-4 inhibitors, it works by increasing endogenously produced GLP-1 and GIP. In a phase 3 trial it showed similar results as alogliptin.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1330279790 under CC BY-SA 4.0; modifications have been made.